Crossmark

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Crossref DOI link: https://doi.org/10.1038/nchembio.2085

Published Online: 2016-05-23

Published Print: 2016-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vinogradova, Maia

Gehling, Victor S

Gustafson, Amy

Arora, Shilpi https://orcid.org/0000-0001-5133-3612
Tindell, Charles A

Wilson, Catherine

Williamson, Kaylyn E

Guler, Gulfem D

Gangurde, Pranoti

Manieri, Wanda

Busby, Jennifer

Flynn, E Megan

Lan, Fei

Kim, Hyo-jin

Odate, Shobu

Cochran, Andrea G

Liu, Yichin

Wongchenko, Matthew

Yang, Yibin

Cheung, Tommy K

Maile, Tobias M

Lau, Ted

Costa, Michael

Hegde, Ganapati V

Jackson, Erica

Pitti, Robert

Arnott, David

Bailey, Christopher

Bellon, Steve

Cummings, Richard T

Albrecht, Brian K

Harmange, Jean-Christophe

Kiefer, James R

Trojer, Patrick

Classon, Marie
License Information

Text and Data Mining valid from 2016-05-23
More Information

Article History

Received: 15 July 2015

Accepted: 6 April 2016

First Online: 23 May 2016

Competing interests

: V.S.G., S.A., K.E.W., W.M., J.B., S.O., C.B., S.B., R.T.C. and P.T. are employees and shareholders of Constellation Pharmaceutical Inc. P.G., F.L., J.-C.H. and B.K.A. are shareholders of Constellation Pharmaceutical Inc. All other authors are employees of Genentech Inc. and may hold stock in the Roche Group.